Latest & greatest articles for alzheimer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alzheimer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alzheimer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Alzheimer’s disease

Alzheimer’s disease is a chronic neurodegenerative disease responsible for the majority of cases of dementia. This progressive disease disrupts memory and thinking due to an accumulation of plaques and tangles in the brain. As the disease progresses, these get progressively worse.

What causes Alzheimer’s diseases is poorly understood, although there is a strong genetic component which could account for the majority (~70%) of the risk. Other risk factors have been identified, such as depression, head injuries and hypertension. Alzheimer’s disease is typically a disease of older people.

Although Alzheimer’s disease cannot currently be cured but it can be managed. With cholinesterase inhibitors being a common intervention as well as memantine (an NMDA receptor antagonist) and psychosocial interventions.

Trip has an extensive collection of research evidence and articles relating to Alzheimer’s disease including clinical guidelines, systematic reviews, synopses, clinical trials and case reports.

Top results for alzheimer

61. Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI).

Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). BACKGROUND: Dementia is a progressive global cognitive impairment syndrome. In 2010, more than 35 million people worldwide were estimated to be living with dementia. Some people with mild cognitive impairment (MCI) will progress to dementia but others remain stable or recover full function. There is great interest in finding good predictors (...) of dementia in people with MCI. The Mini-Mental State Examination (MMSE) is the best-known and the most often used short screening tool for providing an overall measure of cognitive impairment in clinical, research and community settings. OBJECTIVES: To determine the diagnostic accuracy of the MMSE at various thresholds for detecting individuals with baseline MCI who would clinically convert to dementia in general, Alzheimer's disease dementia or other forms of dementia at follow-up. SEARCH METHODS: We

Cochrane2015

62. Neuropsychiatric Symptoms as Predictors of Progression to Severe Alzheimer`s Dementia and Death: The Cache County Dementia Progression Study

Neuropsychiatric Symptoms as Predictors of Progression to Severe Alzheimer`s Dementia and Death: The Cache County Dementia Progression Study 25585033 2015 05 01 2015 07 17 2016 12 08 1535-7228 172 5 2015 May The American journal of psychiatry Am J Psychiatry Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the Cache County Dementia Progression Study. 460-5 10.1176/appi.ajp.2014.14040480 Little is known about factors influencing the rate (...) of progression of Alzheimer's dementia. Using data from the Cache County Dementia Progression Study, the authors examined the link between clinically significant neuropsychiatric symptoms in mild Alzheimer's dementia and progression to severe dementia or death. The Cache County Dementia Progression Study is a longitudinal study of dementia progression in incident cases of this condition. Survival analyses included unadjusted Kaplan-Meier plots and multivariate Cox proportional hazard models. Hazard ratio

EvidenceUpdates2015

63. Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a community setting.

Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a community setting. BACKGROUND: Alzheimer's disease and related forms of dementia are becoming increasingly prevalent with the aging of many populations. The diagnosis of Alzheimer's disease relies on tests to evaluate cognition and discriminate between individuals with dementia and those without dementia. The Mini-Cog is a brief, cognitive screening test that is frequently used to evaluate cognition in older (...) adults in various settings. OBJECTIVES: The primary objective of this review was to determine the diagnostic accuracy of the Mini-Cog for detecting Alzheimer's disease dementia and related dementias in a community setting.Secondary objectives included investigations of the heterogeneity of test accuracy in the included studies and potential sources of heterogeneity. These potential sources of heterogeneity included the baseline prevalence of dementia in study samples, thresholds used to determine

Cochrane2015

64. Randomised controlled trial: Mediterranean diet may reduce Alzheimer's risk

Randomised controlled trial: Mediterranean diet may reduce Alzheimer's risk Mediterranean diet may reduce Alzheimer's risk | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Mediterranean diet may reduce Alzheimer's risk Article Text Therapeutics/Prevention Randomised controlled trial Mediterranean diet may reduce Alzheimer's risk Theodora Psaltopoulou , Theodoros N Sergentanis Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Valls-Pedret C , Sala-Vila A , Serra-Mir M , et al . Mediterranean diet and age-related

Evidence-Based Medicine (Requires free registration)2015

65. Case?control study: Benzodiazepine exposure increases risk of Alzheimer's disease

Case?control study: Benzodiazepine exposure increases risk of Alzheimer's disease Benzodiazepine exposure increases risk of Alzheimer's disease | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Benzodiazepine exposure increases risk of Alzheimer's disease Article Text Aetiology/Harm Case–control study Benzodiazepine exposure increases risk of Alzheimer's disease Paul B Rosenberg Correspondence to : Johns Hopkins University School of Medicine, 5300 Alpha Commons Drive #429, Baltimore, MD 21224 USA; prosenb9{at}jhmi.edu Statistics from Altmetric.com

Evidence-Based Medicine (Requires free registration)2015

68. Idalopirdine for Alzheimer's disease as an adjunct to acetylcholinesterase inhibitor therapy

Idalopirdine for Alzheimer's disease as an adjunct to acetylcholinesterase inhibitor therapy Idalopirdine for Alzheimer's disease as an adjunct to acetylcholinesterase inhibitor therapy Idalopirdine for Alzheimer's disease as an adjunct to acetylcholinesterase inhibitor therapy NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR (...) HSC. Idalopirdine for Alzheimer's disease as an adjunct to acetylcholinesterase inhibitor therapy. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Alzheimer Diseases; Cholinesterase Inhibitors Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Centre, School of Health

Health Technology Assessment (HTA) Database.2014

69. [Diagnostic usefulness of brain FDG-PET for Alzheimer's dementia]

[Diagnostic usefulness of brain FDG-PET for Alzheimer's dementia] [Diagnostic usefulness of brain FDG-PET for Alzheimer's dementia] [Diagnostic usefulness of brain FDG-PET for Alzheimer's dementia] Ryu YH, Choi JE, Sohn BK, Lyoo CH, Sohn CH, Lee DY, Shin E, Jeong H, Kim H, Kim JY, Shin JH, Lee JY, Byun MS, Lee S, Park SH, Son SK, Choe YM, Lee YE, Kim YK, Lee YK Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Ryu YH, Choi JE, Sohn BK, Lyoo CH, Sohn CH, Lee DY, Shin E, Jeong H, Kim H, Kim JY, Shin JH, Lee JY, Byun MS, Lee S, Park SH, Son SK, Choe YM, Lee YE, Kim YK, Lee YK. [Diagnostic usefulness of brain FDG-PET for Alzheimer's dementia] Seoul: National Evidence-based Healthcare Collaborating Agency (NECA). NECA-C-13-010. 2014 Authors' conclusions We assessed the diagnostic accuracy of FDG-PET in the evaluation of dementia, which

Health Technology Assessment (HTA) Database.2014

71. Risperdal (Risperidone) - schizophrenia and bipolar disorders and persistent aggression in conduct disorder in children and ersistent aggression in patients with moderate to severe Alzheimer's dementia

Risperdal (Risperidone) - schizophrenia and bipolar disorders and persistent aggression in conduct disorder in children and ersistent aggression in patients with moderate to severe Alzheimer's dementia

Haute Autorite de sante2014

72. Help Versus Hope: Acetylcholinesterase Inhibitors in Alzheimer?s Disease

Help Versus Hope: Acetylcholinesterase Inhibitors in Alzheimer?s Disease Help Versus Hope: Acetylcholinesterase Inhibitors in Alzheimer’s Disease | Clinical Correlations Help Versus Hope: Acetylcholinesterase Inhibitors in Alzheimer’s Disease May 21, 2014 By Jonathan Gursky Peer Reviewed ) [1], with this [2]. Alzheimer’s disease is now the sixth leading cause of death in the United States [3] and accounts for $100 billion in healthcare expenditures each year [1]. Nevertheless, the most (...) devastating and far-reaching effects of Alzheimer’s disease hit close to home. While those with the disease progressively lose their memory, speech, and independence, it is the caretaker who often bears the brunt of the burden. Not surprisingly, an estimated 23.5% of spouses of a person with Alzheimer’s disease [4]. Overall, the mortality from any cause among caretakers of [5]. Alzheimer’s disease is a slowly progressive disease of the [6]. As the disease advances, patients require higher levels of care

Clinical Correlations2014

73. Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) as a Predictor of Conversion from Mild Cognitive Impairment to Alzheimer`s Disease

Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) as a Predictor of Conversion from Mild Cognitive Impairment to Alzheimer`s Disease 24635004 2014 04 15 2014 06 03 2016 11 25 1532-5415 62 4 2014 Apr Journal of the American Geriatrics Society J Am Geriatr Soc Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer's disease. 679-84 10.1111/jgs.12742 To assess the usefulness of the Montreal Cognitive Assessment (...) (MoCA) total score (MoCA-TS) and Memory Index Score (MoCA-MIS) in predicting conversion to Alzheimer's disease (AD) in individuals with mild cognitive impairment (MCI). Retrospective chart review. Community-based memory clinic. Individuals meeting Petersen's MCI criteria (N = 165). Baseline MoCA scores at MCI diagnosis were collected from charts of eligible individuals with MCI, and MoCA-TS, MoCA-MIS, and a cognitive domain index score were calculated to assess their prognostic value in predicting

EvidenceUpdates2014

74. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.

Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. IMPORTANCE: Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory. OBJECTIVE: The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease. Key secondary objectives examined effects of citalopram on function (...) , caregiver distress, safety, cognitive safety, and tolerability. DESIGN, SETTING, AND PARTICIPANTS: The Citalopram for Agitation in Alzheimer Disease Study (CitAD) was a randomized, placebo-controlled, double-blind, parallel group trial that enrolled 186 patients with probable Alzheimer disease and clinically significant agitation from 8 academic centers in the United States and Canada from August 2009 to January 2013. INTERVENTIONS: Participants (n = 186) were randomized to receive a psychosocial

JAMA2014

75. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. BACKGROUND: Alzheimer's disease is characterized by amyloid-beta plaques, neurofibrillary tangles, gliosis, and neuronal loss. Solanezumab, a humanized monoclonal antibody, preferentially binds soluble forms of amyloid and in preclinical studies promoted its clearance from the brain. METHODS: In two phase 3, double-blind trials (EXPEDITION 1 and EXPEDITION 2), we randomly assigned 1012 and 1040 patients, respectively (...) , with mild-to-moderate Alzheimer's disease to receive placebo or solanezumab (administered intravenously at a dose of 400 mg) every 4 weeks for 18 months. The primary outcomes were the changes from baseline to week 80 in scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11; range, 0 to 70, with higher scores indicating greater cognitive impairment) and the Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL; range, 0 to 78

NEJM2014

76. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab (...) or placebo, with doses varying by study, was administered by intravenous infusion every 13 weeks for 78 weeks. The primary outcome measures were scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11, with scores ranging from 0 to 70 and higher scores indicating greater impairment) and the Disability Assessment for Dementia (DAD, with scores ranging from 0 to 100 and higher scores indicating less impairment). A total of 1090 carriers and 1114 noncarriers were

NEJM2014

77. Swallowing Dysfunction and Autonomic Nervous System Dysfunction in Alzheimer`s Disease: A Scoping Review of the Evidence

Swallowing Dysfunction and Autonomic Nervous System Dysfunction in Alzheimer`s Disease: A Scoping Review of the Evidence 24329892 2014 01 29 2014 02 13 2014 01 29 1532-5415 61 12 2013 Dec Journal of the American Geriatrics Society J Am Geriatr Soc Swallowing dysfunction and autonomic nervous system dysfunction in Alzheimer's disease: a scoping review of the evidence. 2203-13 To describe, synthesize, and interpret literature on swallowing impairment (dysphagia) and autonomic nervous system (ANS (...) ) dysfunction in Alzheimer's disease (AD) and to identify gaps in the existing literature. Scoping review of literature covering several study designs. Literature review. Individuals with AD. Systematic searches of the PubMed, EBSCOhost, PsychINFO, Cochrane, EMBASE, and Scopus databases were conducted. Literature was identified and organized into categories. Studies were then evaluated using the Oxford Centre for Evidence-Based Medicine Levels of Evidence criteria. After evaluation, the literature

EvidenceUpdates2014

78. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.

Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. 24549548 2014 02 19 2014 02 24 2016 12 15 1538-3598 311 7 2014 Feb 19 JAMA JAMA Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. 682-91 10.1001/jama.2014.93 Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory. The primary (...) objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease. Key secondary objectives examined effects of citalopram on function, caregiver distress, safety, cognitive safety, and tolerability. The Citalopram for Agitation in Alzheimer Disease Study (CitAD) was a randomized, placebo-controlled, double-blind, parallel group trial that enrolled 186 patients with probable Alzheimer disease and clinically significant agitation from 8 academic centers in the United

JAMA2014 Full Text: Link to full Text with Trip Pro

79. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. 24450891 2014 01 23 2014 02 04 2016 12 15 1533-4406 370 4 2014 Jan 23 The New England journal of medicine N. Engl. J. Med. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. 322-33 10.1056/NEJMoa1304839 Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. We conducted two double-blind, randomized, placebo-controlled (...) , phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying by study, was administered by intravenous infusion every 13 weeks for 78 weeks. The primary outcome measures were scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11, with scores ranging from 0 to 70 and higher scores

NEJM2014 Full Text: Link to full Text with Trip Pro

80. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.

Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. 24381967 2014 01 01 2014 01 13 2017 02 20 1538-3598 311 1 2014 Jan 01 JAMA JAMA Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. 33-44 10.1001/jama.2013.282834 Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited (...) ), the combination (n = 154), or placebo (n = 152). Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) Inventory score (range, 0-78). Secondary outcomes included cognitive, neuropsychiatric, functional, and caregiver measures. Data from 561 participants were analyzed (alpha tocopherol = 140, memantine = 142, combination = 139, placebo = 140), with 52 excluded because of a lack of any follow-up data. Over the mean (SD) follow-up of 2.27 (1.22) years, ADCS-ADL Inventory scores declined

JAMA2014 Full Text: Link to full Text with Trip Pro